問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Dermatology

Taipei Chang Gung Medical Foundation

Division of Dermatology

更新時間:2023-09-19

張雅菁Chang, Ya-Ching
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years 1 個月

篩選

List

44Cases

2025-11-01 - 2030-06-07

Others

Active
A phase 3b/4, multicenter, randomized, open-label, long-term safety trial comparing deucravacitinib with ustekinumab in participants with moderate to severe plaque psoriasis (PRAGMATYK).
  • Condition/Disease

    Participants with moderate to severe plaque psoriasis (PRAGMATYK)

  • Test Drug

    Shu Ting Coated Tablets 6 mg

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2025-11-03 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of OBI- 858 in Subjects with Moderate to Severe Glabellar Lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    Freeze-dried injection

Participate Sites
8Sites

Recruiting8Sites

2025-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2026-05-01 - 2027-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-01-01 - 2027-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-10-10 - 2027-07-14

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-10-01 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2026-01-05 - 2028-05-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting7Sites

1 2 3 4 5